CJC-1295 / Ipamorelin Blend

CJC-1295 (No DAC) / Ipamorelin Blend combines two research peptides that signal through different receptor systems connected with growth-hormone biology. CJC-1295 (No DAC) is studied through the GHRH receptor, while ipamorelin is studied through the ghrelin receptor.

Researchers use the combination to examine how two distinct upstream signals may interact within the same growth-hormone research axis.

Technical Identity: This blend is commonly characterized by two peptide components: a CJC-1295 (No DAC) / modified GHRH-related peptide and ipamorelin, a synthetic growth-hormone secretagogue peptide.

Azyven Research CJC-1295 / Ipamorelin Blend is supplied exclusively for laboratory research and analytical use.

What is CJC-1295 / Ipamorelin Blend?

This formulation combines a GHRH-related peptide with a selective growth hormone secretagogue. Each component engages a different receptor system involved in regulating pituitary growth-hormone release.

Why is CJC-1295 / Ipamorelin Blend studied?

The blend has attracted research interest because GHRH-receptor signaling and ghrelin-receptor signaling represent complementary routes into the growth-hormone axis.

Researchers use the combination to examine receptor interactions, endocrine signaling, growth-hormone release, and how multiple upstream signals can converge on the same biological system.

What research areas are associated with CJC-1295 / Ipamorelin Blend?

GHRH-Receptor Research
CJC-1295 (No DAC) contributes GHRH-related signaling to the formulation.

Ghrelin-Receptor Research
Ipamorelin is studied for selective activity at the growth hormone secretagogue receptor.

Growth-Hormone Signaling Research
Both components are associated with pathways regulating pituitary growth-hormone release.

Growth Hormone / IGF-1 Axis Research
The blend provides a model for studying downstream endocrine responses connected with growth-hormone signaling.

Multi-Pathway Endocrine Research
Researchers can investigate how distinct receptor systems influence a shared hormonal pathway.

What have studies found?

The two components have separate research histories that help explain the scientific rationale for studying them together.

CJC-related signaling
Research on GHRH analogues has examined pituitary growth-hormone release and downstream endocrine signaling.

Ipamorelin signaling
Studies have reported selective growth-hormone secretagogue activity associated with ghrelin-receptor signaling.

Complementary pathways
The formulation allows researchers to examine two receptor systems that can converge on growth-hormone release.

Evidence context
Findings for either component individually do not establish the behavior of the combined formulation. The blend should be evaluated as its own research system.

How does CJC-1295 / Ipamorelin Blend relate to other Azyven products?

Azyven also offers CJC-1295 (No DAC) and Ipamorelin as standalone research peptides, allowing each receptor pathway to be examined independently.

Sermorelin and Tesamorelin provide additional GHRH-related comparison points within the Azyven catalog.

Researchers can ask Aria Jr. to compare the individual components, receptor systems, or blend format.

What am I purchasing?

Azyven Research CJC-1295 / Ipamorelin Blend is supplied as a lyophilized combination research material.

Available Strength: 10 mg
Form: Lyophilized powder
Product Type: Research Peptide Blend
Intended Use: Laboratory research only

Research Use Only: Azyven Research products are intended for laboratory research purposes only. They are not intended for human or veterinary use, consumption, administration, or clinical application.